ライフサイエンスコーパス: myelomonocytic

1 IFP expression was sufficient to induce a myelomonocytic AML even when expressed in wild type bone

2 giogenesis involves both bone marrow-derived myelomonocytic and endothelial progenitor cells as well

3 nd with their ability to give rise to mature myelomonocytic and lymphoid cells.

4 rminal kinase signaling pathways, leading to myelomonocytic and monocytic AML cell differentiation.

5 We report that a subset of malignant myelomonocytic and monocytic AML cells (French-American-

6 n leukemia and have therapeutic potential in myelomonocytic and monocytic AMLs.

7 ith impaired mobilization of endothelial and myelomonocytic angiogenic progenitors from the bone marr

8 o, which is characterized by the presence of myelomonocytic blasts and atypical eosinophils.

9 TCL1 was also expressed in myelomonocytic blasts of 3 transformed BT cases but not

10 al precursor cells and "vascular modulatory" myelomonocytic (CD11b+) cells.

11 the myeloid compartment that evoked a clonal myelomonocytic cell expansion, splenomegaly, multi-organ

12 Basic research into human mature myelomonocytic cell function, myeloid lineage diversific

13 7 constructs were introduced into the murine myelomonocytic cell line, 32D, and assayed for their eff

14 Moreover, when tested in a porcine myelomonocytic cell line, NSP1beta inhibited Sendai viru

15 Using the THP-1 myelomonocytic cell line, we demonstrated for the first

16 Human myelomonocytic cell lines accurately model PLD-dependent

17 Using chick HD-11 and human THP-1 myelomonocytic cell lines, we have shown that macrophage

18 ement to direct activity of reporter gene in myelomonocytic cell lines.

19 onocytic leukemia (JMML) is characterized by myelomonocytic cell overproduction and commonly bears ac

20 results in a hyperproliferative response of myelomonocytic cell populations to growth factor stimula

21 eam to salivary glands and is dependent on a myelomonocytic cell type other than mature macrophages.

22 ) ASCs in the medullary cords migrated along myelomonocytic cells and arrested in contact with them.

23 However, PR expression in U937 myelomonocytic cells and primary murine myeloid bone mar

24 Peripheral blood myelomonocytic cells are important for cytomegalovirus d

25 The role of inflammatory myelomonocytic cells as mediators of these processes and

26 ne expression in monocytes, macrophages, and myelomonocytic cells as well as in epidermal keratinocyt

27 e and found EYFP gene expression not only in myelomonocytic cells but also in a fraction of HSCs as w

28 y described a mouse line that contains green myelomonocytic cells due to the knock-in of enhanced gre

29 dissect the branching between erythroid and myelomonocytic cells during in vitro differentiation of

30 grade Abeta(1-42), and ACE overexpression in myelomonocytic cells enhances their immune function.

31 Macrophages, THP-1 cells, and other human myelomonocytic cells expressed both PLD1 and PLD2 protei

32 o generate large numbers of patient-specific myelomonocytic cells for in vitro studies of human disea

33 porting this hypothesis, Siglec-9-expressing myelomonocytic cells found in human tumor samples were a

34 a similar protocol could be used to generate myelomonocytic cells from induced pluripotent stem cells

35 inct roles that reflect the dual function of myelomonocytic cells in cancer progression.

36 ses monoblastic leukemia and transforms only myelomonocytic cells in culture.

37 tions, spanning progenitor to mature myeloid/myelomonocytic cells in normal bone marrows with further

38 erm repopulating cells give rise to expanded myelomonocytic cells in vivo.

39 Myelomonocytic cells play a key role in the progression

40 The overexpression of ACE and iNOS by myelomonocytic cells substantially boosts innate immunit

41 sults provide direct evidence that committed myelomonocytic cells such as macrophages can produce fun

42 However, myelomonocytic cells such as neutrophils have also been

43 iocytes (FLS) cell lines that were bereft of myelomonocytic cells to examine whether mesenchymal-deri

44 nctional analyses revealed that hESC-derived myelomonocytic cells were comparable to their correspond

45 omposed of myeloperoxidase-positive immature myelomonocytic cells with histiocytoid morphology.

46 to ILT4 leads to a tolerogenic phenotype of myelomonocytic cells with lower surface expression of de

47 cognition by innate MHC class I receptors on myelomonocytic cells, and functional impairment of DCs,

48 on maternal uterine natural killer (NK) and myelomonocytic cells, CD94/NKG2, leukocyte immunoglobuli

49 Among DC-HIL(+) myelomonocytic cells, during growth of implanted mouse m

50 rrow of the lys-EGFP mice revealed that most myelomonocytic cells, especially mature neutrophil granu

51 ifferentiation in certain cell types, namely myelomonocytic cells, osteoblasts, skeletal muscle cells

52 lineage, they do not include mature CD11b(+) myelomonocytic cells, such as macrophages.

53 ermore, GATA-1 induced apoptosis of proB and myelomonocytic cells, which could not be prevented by en

54 re also detected in transduced human PLB-985 myelomonocytic cells.

55 characterized by excessive proliferation of myelomonocytic cells.

56 tiple chemoattractants capable of recruiting myelomonocytic cells.

57 mechanisms and rely instead on CTL-recruited myelomonocytic cells.

58 y MHC class I-specific receptor expressed on myelomonocytic cells.

59 opment and in the maturation and function of myelomonocytic cells.

60 low amounts of BAFF mRNA relative to that of myelomonocytic cells.

61 epatocytes are primarily derived from mature myelomonocytic cells.

62 eversed by transgenic Siglec-9 expression in myelomonocytic cells.

63 Endothelial progenitor cells (EPCs) and myelomonocytic circulating angiogenic cells (CACs) are c

64 a reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.

65 and C/EBPalpha (Cebpa) have general roles in myelomonocytic development, but the transcriptional basi

66 l antibody directed against the cell surface myelomonocytic differentiation antigen CD33.

67 tion exhibiting increased cell cycling and a myelomonocytic differentiation bias.

68 c cells rescued the PU.1 knockdown-initiated myelomonocytic differentiation block.

69 lso been described, but a role for TIMP-1 in myelomonocytic differentiation has not been previously r

70 ology, and exhibited increased expression of myelomonocytic differentiation markers, including CD11b,

71 action of pro-T cells possess plasticity for myelomonocytic differentiation that can be activated by

72 ogenitors expressing activating Shp2 undergo myelomonocytic differentiation, despite being subjected

73 uration arrest at an identical late stage of myelomonocytic differentiation, putatively a monopotent

74 rylation, expression of RIG-E and RIG-G, and myelomonocytic differentiation-specific down-regulation

75 nitors preserves CD34 expression and impairs myelomonocytic differentiation.

76 ithin 96 hours, parallel to the induction of myelomonocytic differentiation.

77 MafB is a transcription factor that induces myelomonocytic differentiation.

78 nced immune response, coupled with increased myelomonocytic expression of catalytically active ACE, p

79 ltipotential progenitor cell maintenance and myelomonocytic fate and suggests Glut1 as potential drug

80 ts EPO-stimulated HSCs to differentiate into myelomonocytic fates, altering in vivo HSC responses and

81 le attractors corresponding to erythroid and myelomonocytic fates, as well as an uncommitted metastab

82 ch regulate the choice between erythroid and myelomonocytic fates.

83 ere mainly mediated by interactions with the myelomonocytic HLA class I receptor leukocyte immunoglob

84 -N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myelo

85 MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemia

86 of developing leukaemia, especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloprolif

87 ere applied to BALB/c mice with transplanted myelomonocytic leukaemia (WEHI-3) and Human promyelocyti

88 astic syndromes or non-proliferative chronic myelomonocytic leukaemia (white blood cell count <13 000

89 blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on local site assessment,

90 in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative

91 with blast-phase disease), one with chronic myelomonocytic leukaemia, and seven with myelofibrosis.

92 eukaemia, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, myelodysplastic syndrome, or m

93 s study, we address this question in chronic myelomonocytic leukaemia.

94 enes for polycystic kidney disease and acute myelomonocytic leukaemia.

95 ximately 75% incidence) and SRSF2 in chronic myelomonocytic leukemia ( approximately 28% incidence).

96 ed patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75

97 Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocyt

98 s of myeloid malignancies resembling chronic myelomonocytic leukemia (CMML) and myelodysplastic syndr

99 B fusion oncogene is associated with chronic myelomonocytic leukemia (CMML) and results in the expres

100 ations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML

101 Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by muta

102 myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases.

103 However, monocytoid precursors in chronic myelomonocytic leukemia (CMML) expressed VEGF in an inte

104 3;p13) translocation associated with chronic myelomonocytic leukemia (CMML) generates a TEL/PDGFbetaR

105 Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational l

106 mouse model resemble those of human chronic myelomonocytic leukemia (CMML) in its transformation to

107 Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic

108 Chronic myelomonocytic leukemia (CMML) is a hematologic malignan

109 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic synd

110 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myel

111 The natural course of chronic myelomonocytic leukemia (CMML) is highly variable but a

112 Here, we showed that chronic myelomonocytic leukemia (CMML) patients with ASXL1 mutat

113 myeloid leukemia (AML) patients, 32 chronic myelomonocytic leukemia (CMML) patients, and 96 healthy

114 us pathogenesis to those observed in chronic myelomonocytic leukemia (CMML) patients.

115 Human ASXL1 is mutated frequently in chronic myelomonocytic leukemia (CMML) so an ASXL/BAP1 complex m

116 Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3

117 omic DNA from 245 patients--119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hy

118 oring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some

119 Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myelop

120 myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukem

121 (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endom

122 e myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML), including identical soma

123 tion, with a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was serially trans

124 ras G12D/+ bone marrow cells develop chronic myelomonocytic leukemia (CMML), while approximately 8% o

125 ng the myeloproliferative variant of chronic myelomonocytic leukemia (CMML), with a prolonged latency

126 NRAS rapidly and efficiently induced chronic myelomonocytic leukemia (CMML)- or acute myeloid leukemi

127 MPN that accurately models JMML and chronic myelomonocytic leukemia (CMML).

128 n of SRSF2 (Pro95) in 275 cases with chronic myelomonocytic leukemia (CMML).

129 myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

130 iferative neoplasm, similar to human chronic myelomonocytic leukemia (CMML).

131 clonal malignancy closely resembling chronic myelomonocytic leukemia (CMML).

132 cogenes in a subset of patients with chronic myelomonocytic leukemia (CMML).

133 been reported in some patients with chronic myelomonocytic leukemia (CMML).

134 T2-WT) and mutant (TET2-MT) cases of chronic myelomonocytic leukemia (CMML).

135 y shown in the related human disease chronic myelomonocytic leukemia (CMML).

136 ent in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogen

137 yeloid malignancies, particularly in chronic myelomonocytic leukemia (CMML; 48%) and MDS/MPD-unclassi

138 with excess blasts (RAEB), and 1 had chronic myelomonocytic leukemia (CMMoL).

139 y members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemi

140 features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myelomonocyti

141 acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML) and LEOPARD syndrome freq

142 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated m

143 matopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymphoblastic

144 ctive RAS signaling is prevalent in juvenile myelomonocytic leukemia (JMML) and the myeloproliferativ

145 myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndr

146 ) hypersensitivity is a hallmark of juvenile myelomonocytic leukemia (JMML) but has not been systemat

147 ndividuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations i

148 Juvenile myelomonocytic leukemia (JMML) is a disease that occurs

149 Juvenile myelomonocytic leukemia (JMML) is a lethal disease of yo

150 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative d

151 Juvenile myelomonocytic leukemia (JMML) is a pediatric myeloproli

152 Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive

153 Juvenile myelomonocytic leukemia (JMML) is a rare clonal myelopro

154 Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myelo

155 Juvenile myelomonocytic leukemia (JMML) is a typically aggressive

156 Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive h

157 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

158 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

159 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

160 Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatri

161 Juvenile myelomonocytic leukemia (JMML) is characterized by hyper

162 Juvenile myelomonocytic leukemia (JMML) is characterized by myelo

163 myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fash

164 ting the molecular underpinnings of juvenile myelomonocytic leukemia (JMML) with the generation of in

165 own to underlie the pathogenesis of juvenile myelomonocytic leukemia (JMML), a fatal childhood diseas

166 s individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferati

167 PTPN11 (SHP-2) are associated with juvenile myelomonocytic leukemia (JMML), a myeloproliferative dis

168 sis type 1 (NF1) are predisposed to juvenile myelomonocytic leukemia (JMML), an aggressive myeloproli

169 al investigate the pathogenesis of juvenile myelomonocytic leukemia (JMML), demonstrating that mutan

170 ood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which is a myeloprolifer

171 L, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML).

172 associated with an elevated risk of juvenile myelomonocytic leukemia (JMML).

173 patients with de novo, nonsyndromic juvenile myelomonocytic leukemia (JMML).

174 of hematologic disorders, including juvenile myelomonocytic leukemia (JMML).

175 (ras), is frequently inactivated in juvenile myelomonocytic leukemia (JMML).

176 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML).

177 ferative disorders (MPD), including juvenile myelomonocytic leukemia (JMML).

178 nd the myeloproliferative variant of chronic myelomonocytic leukemia (JMML/MP-CMML).

179 nd the myeloproliferative variant of chronic myelomonocytic leukemia (MP-CMML) in humans, and both ar

180 ures and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those

181 ease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70

182 and SRSF2 mutations are frequent in chronic myelomonocytic leukemia and advanced forms of MDS.

183 tions are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as d

184 e-1 (FIP1L1)-PDGFRalpha, which cause chronic myelomonocytic leukemia and hypereosinophilic syndrome,

185 tantly, Bcl11a is expressed in human chronic myelomonocytic leukemia and juvenile myelomonocytic leuk

186 closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myeloproliferative neopl

187 We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with system

188 uting to the pathogenesis of NS and juvenile myelomonocytic leukemia caused by PTPN11 gain-of-functio

189 MLL-AF6 leukemias as well as in ML2, a human myelomonocytic leukemia cell line bearing the t(6;11)(q2

190 lcytosine (ara-C)-induced apoptosis in human myelomonocytic leukemia cells (U937).

191 Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nM flavopiridol and

192 detection of shared origin of LCH and acute myelomonocytic leukemia driven by TET2-mutant CD34(+) ce

193 Juvenile myelomonocytic leukemia is an aggressive and frequently

194 Juvenile myelomonocytic leukemia is an aggressive myeloproliferat

195 In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that

196 BCOR is also mutated in chronic myelomonocytic leukemia patients (7.4%) and BCORL1 in AM

197 n 161 of 1458 patients (11%); 26% of chronic myelomonocytic leukemia patients harbored 7q uniparental

198 Juvenile myelomonocytic leukemia patients without PTPN11 mutation

199 Decitabine's mechanism of action in chronic myelomonocytic leukemia remains incompletely understood.

200 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia samples.

201 lomonocytic origin, and a diagnosis of acute myelomonocytic leukemia was rendered.

202 Patients with chronic myelomonocytic leukemia were first screened for JAK2 and

203 actory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0

204 mia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% bone marrow blasts, 63

205 ronic myeloproliferative syndrome or chronic myelomonocytic leukemia with eosinophilia.

206 acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.

207 MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia).

208 ferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia, 28 (23%) myelodysplastic syndro

209 clinical and molecular features with chronic myelomonocytic leukemia, a similar disease in adults.

210 liferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International

211 Juvenile myelomonocytic leukemia, acute myeloid leukemia (AML), a

212 n specific human cancers, including juvenile myelomonocytic leukemia, an aggressive myeloproliferativ

213 tic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with

214 h myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leuk

215 roblasts, TET2/SRSF2 comutation with chronic myelomonocytic leukemia, and activating CSF3R mutation w

216 All subtypes of myelodysplasia, chronic myelomonocytic leukemia, and acute myeloid leukemia with

217 re common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome.

218 r gene is frequently inactivated in juvenile myelomonocytic leukemia, and Nf1 mutant mice model this

219 ted with marked thrombocytosis, and juvenile myelomonocytic leukemia, are clonal hematologic diseases

220 tive neoplasms (MDS/MPNs), including chronic myelomonocytic leukemia, atypical chronic myeloid leukem

221 ectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unrelated do

222 Chronic myelomonocytic leukemia, isolated 5q- syndrome, unclassi

223 ons occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell

224 s SM-MPN, systemic mastocytosis with chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytos

225 ed in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hyper

226 antation model efficiently induces a chronic myelomonocytic leukemia- or acute myeloid leukemia-like

227 ents suffering from MDS (n = 52) and chronic myelomonocytic leukemia-1 (n = 2).

228 d SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia.

229 A 3-year-old boy was treated for juvenile myelomonocytic leukemia.

230 econdary acute myeloid leukemia, and chronic myelomonocytic leukemia.

231 , genomic instability, and aggressive, fatal myelomonocytic leukemia.

232 s, myeloproliferative neoplasms, and chronic myelomonocytic leukemia.

233 bling the myeloproliferative form of chronic myelomonocytic leukemia.

234 n found in a subset of patients with chronic myelomonocytic leukemia.

235 ice that closely models juvenile and chronic myelomonocytic leukemia.

236 eloproliferative disorder resembling chronic myelomonocytic leukemia.

237 loid metaplasia, and, less commonly, chronic myelomonocytic leukemia.

238 es, including an increased risk for juvenile myelomonocytic leukemia.

239 viously described BTs with transformation to myelomonocytic leukemia.

240 ws efficacy in a nude mouse model of chronic myelomonocytic leukemia.

241 duct of the t(5;12) translocation in chronic myelomonocytic leukemia.

242 ight loss as initial manifestations of acute myelomonocytic leukemia.

243 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

244 d growth factor beta receptor causes chronic myelomonocytic leukemia.

245 in leukemic cells of a patient with chronic myelomonocytic leukemia.

246 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

247 tosis, including but not limited to, chronic myelomonocytic leukemia.

248 No patient with JXG developed chronic myelomonocytic leukemia.

249 ren with CBL syndrome and transient juvenile myelomonocytic leukemia.

250 elevant proportion of children with juvenile myelomonocytic leukemia.

251 yelodysplastic syndromes (MDSs), and chronic myelomonocytic leukemia.

252 sented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/

253 nduced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/myeloproliferati

254 true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell

255 uch as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced b

256 derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/M

257 g and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs).

258 ptor (TEL-PDGFbetaR) is expressed in chronic myelomonocytic leukemias associated with t(5;12)(q33;p13

259 Myelomonocytic leukemic cells from primary or transplant

260 ave shown that MCK-2-enhanced recruitment of myelomonocytic leukocytes with an immature phenotype occ

261 rin CD11b is a differentiation marker of the myelomonocytic lineage and an important mediator of infl

262 ominantly expressed in immature cells of the myelomonocytic lineage and in a subset of CD11b (Mac-1)-

263 is an autoinflammatory syndrome in which the myelomonocytic lineage appears to play a pivotal role.

264 Potential immunomodulatory receptors on myelomonocytic lineage cells that bind extracellular Hsp

265 pressed by monocytes, macrophages, and other myelomonocytic lineage cells.

266 lves with sialic acids, which can engage the myelomonocytic lineage inhibitory receptor Siglec-9, the

267 HPCs impaired their differentiation into the myelomonocytic lineage, it potently promoted hemoglobin

268 s in mature lysozyme-expressing cells of the myelomonocytic lineage.

269 They develop from hematopoietic cells of the myelomonocytic lineage.

270 eutrophils, monocytes, or tumor cells of the myelomonocytic lineage.

271 ne marrow cells skews differentiation toward myelomonocytic lineage.

272 identified the presence of B cells, several myelomonocytic lineages, fibroblast and epithelial cell

273 as early (pu.1) and late (mpo and l-plastin) myelomonocytic lineages.

274 uce macrophage morphology or upregulation of myelomonocytic markers in U937 cells, suggesting that th

275 lex because upregulation of some but not all myelomonocytic markers required endogenous PU.1.

276 sibility and expression of genes involved in myelomonocytic maturation and differentiation.

277 Long-term cultures displayed a myelomonocytic morphology while retaining multilineage p

278 c-KIT and provide the first animal model of myelomonocytic neoplasia initiated by human KIT(D816V).

279 normal blood monocytes and on tumor cells of myelomonocytic origin was demonstrated.

280 sults confirmed that the infiltrate was of a myelomonocytic origin, and a diagnosis of acute myelomon

281 blastoid, lymphoid-appearing, and subsequent myelomonocytic phases of this disease.

282 retrovirus-induced myeloid leukemias of the myelomonocytic phenotype were found to have hypermethyla

283 is a hematopoietic stem cell derivative, the myelomonocytic precursor (MMC).

284 vitro, HOXB6 immortalized a factor-dependent myelomonocytic precursor capable of granulocytic and mon

285 We used the myelomonocytic precursor M1 cell line to study BeAn viru

286 only fractions containing c-kit(+) immature myelomonocytic precursors are capable of contributing to

287 for PU.1 has been shown to cause a shift in myelomonocytic progenitor fate toward the myeloid lineag

288 in primary murine marrow immortalizes a late myelomonocytic progenitor, preventing it from executing

289 in the pool of hematopoietic cells known as myelomonocytic progenitors.

290 eloid NK precursors are derived from granulo-myelomonocytic progenitors.

291 exclusively to myeloid progenitors and their myelomonocytic progeny.

292 ost response and causes a marked increase in myelomonocytic recruitment with an immature phenotype to

293 previously unidentified impact of inhibitory myelomonocytic Siglecs in cancer biology, with distinct

294 To investigate the function of inhibitory myelomonocytic Siglecs in vivo we studied mouse Siglec-E

295 ast, inflammatory monocytes, the other major myelomonocytic subset, remain virus negative.

296 lete TFPI-K1 in endothelial (TFPI(Tie2)) and myelomonocytic (TFPI(LysM)) cells resulted in viable and

297 ray of cytokines in stably transfected human myelomonocytic U937 cells in response to other TLR agoni

298 tigated by examining the localization of pro-myelomonocytic U937 cells into synovial tissue transplan

299 endogenous TNFalpha.TNFR complexes in human myelomonocytic U937 cells.

300 lls was improved, with an increased ratio of myelomonocytic verus lymphoid lineages.